NSE: ATUL | BSE: 500027

Mid-range Performer

Download real time

6115.50 -61.00 (-0.99%)

39,956 NSE+BSE Volume

NSE 23 Sep, 2026 3:22 PM (IST)

18,005.1

Market Cap

High in industry

Beta 1Year

Very Low volatility

Atul Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ATUL, BSE:500027 Atul Ltd.

Search Inside the pdf :

Atul Ltd.

27 Jul 2026

6115.50

-0.99%

Chemical inflation tailwinds

Buy: Atul Ltd.

Recommendation Target

ICICI Securities Limited

Atul Ltd’s (Atul) Q1FY27 EBITDA jumped 67.1% YoY and was likely supported by inventory gains and a jump in spreads in the domestic market, which are unlikely to sustain.

Atul Ltd. is trading below all available SMAs

Atul Ltd.

25 Jul 2026

6115.50

-0.99%

Robust performance led by performance chemicals

Buy: Atul Ltd.

Target

Motilal Oswal

Atul (ATLP) reported a strong performance in 1QFY27 as revenue grew 25% YoY to INR18.5b, led by 34% YoY revenue growth in the Performance & Other Chemicals segment, while the Life Science Chemical segment’s revenue rose 4% YoY.

Atul Ltd. is trading below all available SMAs

Atul Ltd.

30 Apr 2026

6115.50

-0.99%

Strong volume traction underpins consistent revenue growth

Buy: Atul Ltd.

Target

Motilal Oswal

Atul (ATLP) reported in-line revenue of INR16.7b (+15% YoY) and INR62.7b (+12% YoY) in 4QFY26 and FY26, respectively, predominantly from improved volumes +13%/10% in 4QFY26/FY26, led by recently completed projects.

Promoters unpledged 0.01% of shares in last quarter. Total pledge stands at 0.97% of promoter holdings

Atul Ltd.

25 Jan 2026

6115.50

-0.99%

Growth momentum sustains with the performance segment at the core

Buy: Atul Ltd.

Target

Motilal Oswal

Atul (ATLP) reported in-line revenue of INR15.7b (+11% YoY) in 3QFY26. Revenue from the Performance & Other Chemicals segment increased 11% YoY, while the Life Science Chemical segment’s revenue rose 9% YoY.

Atul Ltd. has an average target of 8050.00 from 2 brokers.

Atul Ltd.

19 Jul 2025

6115.50

-0.99%

Muted EBITDA performance in Q1; business mix deteriorates

Hold: Atul Ltd.

ICICI Securities Limited

Atul Ltd’s (Atul) Q1FY26 EBITDA rose just 5.5% YoY at INR 2.4bn, and was hurt from under-performance in standalone business where EBITDA declined 12.5%; entire growth came from subsidiaries (up 93% YoY).

Promoters unpledged 0.01% of shares in last quarter. Total pledge stands at 0.97% of promoter holdings

Atul Ltd.

18 Jul 2025

6115.50

-0.99%

Performance segment leads the recovery

Buy: Atul Ltd.

Target

Motilal Oswal

Atul (ATLP) reported in-line revenue at INR14.78b (+12% YoY) in 1QFY26. Revenue of the Performance & Other Chemicals segment increased 14% YoY, while the Life Science Chemical segment posted 6% YoY growth.

Atul Ltd. has an average target of 8050.00 from 2 brokers.

Atul Ltd.

06 May 2025

6115.50

-0.99%

Capacity in action: Utilization gains to drive earnings; Buy

Buy: Atul Ltd.

Anand Rathi

Atul invested ~Rs20bn over the last three years in setting up capacity (capex matching the cumulative investment over the last decade). In its analyst meet, management highlighted unrealized sales potential of over Rs25bn from recently concluded capex (~Rs17bn) and from previously unutilized capacity (~Rs8bn).

Atul Ltd. is trading below all available SMAs

Atul Ltd.

03 May 2025

6115.50

-0.99%

Stellar bounce-back in FY25; growth expected to continue

Buy: Atul Ltd.

Target

Motilal Oswal

Atul’s (ATLP) 4QFY25 revenue came in line with our expectation. The Life Science Chemicals (LSC) segment’s revenue increased 18% YoY, while the Performance & Other Chemicals (P&OC) segment’s revenue rose 21% YoY.

Promoters unpledged 0.01% of shares in last quarter. Total pledge stands at 0.97% of promoter holdings

Atul Ltd.

23 Apr 2025, 12:00AM

6115.50

-0.99%

Ripe for volume growth; cheap valuation, favorable risk-reward

Buy: Atul Ltd.

Emkay

We initiate coverage on Atul with BUY and TP of Rs8,500 (30x Mar-27E EPS). Atul has invested ~Rs20bn over FY22-24 toward capacity expansion in existing products like Liquid Epoxy Resin (50ktpa) and Caustic Soda (300tpd), and in the backward integration of some key products (MCA for 2,4 D).

Number of FII/FPI investors increased from 182 to 196 in Jun 2026 qtr.

Atul Ltd.

26 Jan 2025

6115.50

-0.99%

The Life Science segment continues its stellar performance

Buy: Atul Ltd.

Target

Motilal Oswal

Atul (ATLP) reported revenue 7% above our expectation in 3QFY25. Revenue in the Life Science Chemicals segment increased 23% YoY, while it rose 24% YoY in the Performance & Other Chemicals segment

Atul Ltd. is trading below all available SMAs

Is Atul Ltd. worth buying?

188 Votes:

Buy 75.53%

Sell 13.83%

Hold 10.64%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf